Cargando…

SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study

BACKGROUND: Metformin is the most widely used oral antidiabetic agent and can reduce insulin resistance (IR) effectively. Organic cation transporter 1 (encoded by SLC22A1) is responsible for the transport of metformin, and ataxia-telangiectasia-mutated (ATM) is a gene relating to the DNA repair and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kunrong, Li, Xiaoli, Xu, Yuedong, Zhang, Xiaoqian, Guan, Ziwan, Zhang, Shufang, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231067/
https://www.ncbi.nlm.nih.gov/pubmed/32454819
http://dx.doi.org/10.1155/2020/2975898
_version_ 1783535105180958720
author Wu, Kunrong
Li, Xiaoli
Xu, Yuedong
Zhang, Xiaoqian
Guan, Ziwan
Zhang, Shufang
Li, Yan
author_facet Wu, Kunrong
Li, Xiaoli
Xu, Yuedong
Zhang, Xiaoqian
Guan, Ziwan
Zhang, Shufang
Li, Yan
author_sort Wu, Kunrong
collection PubMed
description BACKGROUND: Metformin is the most widely used oral antidiabetic agent and can reduce insulin resistance (IR) effectively. Organic cation transporter 1 (encoded by SLC22A1) is responsible for the transport of metformin, and ataxia-telangiectasia-mutated (ATM) is a gene relating to the DNA repair and cell cycle control. The aim of this study was to evaluate if the genetic variants in SLC22A1 rs622342 and ATM rs11212617 could be effective predictors of islet function improvement in patients with type 2 diabetes mellitus (T2DM) on metformin treatment. METHODS: This cross-sectional study included 111 patients with T2DM treated with metformin. Genotyping was performed by the dideoxy chain-termination method. The homeostatic indexes of IR (HOMA-IR) and beta-cell function (HOMA-BCF) were determined according to the homeostasis model assessment. RESULTS: Fasting plasma glucose (FPG) levels, HbA(1c) levels, and HOMA-IR were significantly higher in patients with the rs622342 AA genotype than in those with C allele (P < 0.05). However, these significant differences were not observed between rs11212617 genotype groups. Further data analysis revealed that the association between the rs622342 polymorphism and HOMA-IR was gender related, and so was rs11212617 polymorphism and HOMA-BCF. HOMA-IR was significantly higher in males with rs622342 AA genotype than in those with C allele (P=0.021), and HOMA-BCF value was significantly higher in females carrying rs11212617 CC genotype than in those with A allele (P=0.038). The common logarithm (Lg10) of HOMA-BCF was positively correlated with the reciprocal of HbA(1c) (r = 0.629, P < 0.001) and negatively associated with Lg10 FPG (r = −0.708, P < 0.001). CONCLUSIONS: The variant of rs622342 could be a predictor of insulin sensitivity in patients with T2DM treated with metformin. The association between the rs622342 polymorphism and HOMA-IR and the association between the rs11212617 polymorphism and HOMA-BCF were both gender related.
format Online
Article
Text
id pubmed-7231067
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72310672020-05-23 SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study Wu, Kunrong Li, Xiaoli Xu, Yuedong Zhang, Xiaoqian Guan, Ziwan Zhang, Shufang Li, Yan Int J Endocrinol Research Article BACKGROUND: Metformin is the most widely used oral antidiabetic agent and can reduce insulin resistance (IR) effectively. Organic cation transporter 1 (encoded by SLC22A1) is responsible for the transport of metformin, and ataxia-telangiectasia-mutated (ATM) is a gene relating to the DNA repair and cell cycle control. The aim of this study was to evaluate if the genetic variants in SLC22A1 rs622342 and ATM rs11212617 could be effective predictors of islet function improvement in patients with type 2 diabetes mellitus (T2DM) on metformin treatment. METHODS: This cross-sectional study included 111 patients with T2DM treated with metformin. Genotyping was performed by the dideoxy chain-termination method. The homeostatic indexes of IR (HOMA-IR) and beta-cell function (HOMA-BCF) were determined according to the homeostasis model assessment. RESULTS: Fasting plasma glucose (FPG) levels, HbA(1c) levels, and HOMA-IR were significantly higher in patients with the rs622342 AA genotype than in those with C allele (P < 0.05). However, these significant differences were not observed between rs11212617 genotype groups. Further data analysis revealed that the association between the rs622342 polymorphism and HOMA-IR was gender related, and so was rs11212617 polymorphism and HOMA-BCF. HOMA-IR was significantly higher in males with rs622342 AA genotype than in those with C allele (P=0.021), and HOMA-BCF value was significantly higher in females carrying rs11212617 CC genotype than in those with A allele (P=0.038). The common logarithm (Lg10) of HOMA-BCF was positively correlated with the reciprocal of HbA(1c) (r = 0.629, P < 0.001) and negatively associated with Lg10 FPG (r = −0.708, P < 0.001). CONCLUSIONS: The variant of rs622342 could be a predictor of insulin sensitivity in patients with T2DM treated with metformin. The association between the rs622342 polymorphism and HOMA-IR and the association between the rs11212617 polymorphism and HOMA-BCF were both gender related. Hindawi 2020-05-08 /pmc/articles/PMC7231067/ /pubmed/32454819 http://dx.doi.org/10.1155/2020/2975898 Text en Copyright © 2020 Kunrong Wu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wu, Kunrong
Li, Xiaoli
Xu, Yuedong
Zhang, Xiaoqian
Guan, Ziwan
Zhang, Shufang
Li, Yan
SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title_full SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title_fullStr SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title_full_unstemmed SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title_short SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study
title_sort slc22a1 rs622342 polymorphism predicts insulin resistance improvement in patients with type 2 diabetes mellitus treated with metformin: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231067/
https://www.ncbi.nlm.nih.gov/pubmed/32454819
http://dx.doi.org/10.1155/2020/2975898
work_keys_str_mv AT wukunrong slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT lixiaoli slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT xuyuedong slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT zhangxiaoqian slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT guanziwan slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT zhangshufang slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy
AT liyan slc22a1rs622342polymorphismpredictsinsulinresistanceimprovementinpatientswithtype2diabetesmellitustreatedwithmetforminacrosssectionalstudy